| Kimberly Dawn Cesare, | |
|
100 Medical Center Dr, Hazard, KY 41701-9421 | |
| (606) 439-6600 | |
| Not Available |
| Full Name | Kimberly Dawn Cesare |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 13 Years |
| Location | 100 Medical Center Dr, Hazard, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1598033086 | NPI | - | NPPES |
| 7100197690 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 3007350 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Sweet Dreams Anesthesia Pllc | 1254757685 | 14 |
News Archive
In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a revolutionary new blood test to diagnose breast cancer.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases.
According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.
› Verified 6 days ago
| Entity Name | Jackson Anesthesia Associates Pa |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1780737577 PECOS PAC ID: 3870585904 Enrollment ID: O20040331000285 |
News Archive
In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a revolutionary new blood test to diagnose breast cancer.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases.
According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.
› Verified 6 days ago
| Entity Name | Sweet Dreams Anesthesia Pllc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1427667724 PECOS PAC ID: 1254757685 Enrollment ID: O20200817002170 |
News Archive
In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a revolutionary new blood test to diagnose breast cancer.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases.
According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Kimberly Dawn Cesare, 425 Lewis Hargett Cir, Lexington, KY 40503-3590 Ph: (859) 268-1030 | Kimberly Dawn Cesare, 100 Medical Center Dr, Hazard, KY 41701-9421 Ph: (606) 439-6600 |
News Archive
In a potential major breakthrough in breast cancer research, scientists at the Center for Translational Cancer Research at the Helen F. Graham Cancer Center & Research Institute of Christiana Care Health System have developed a revolutionary new blood test to diagnose breast cancer.
Durata Therapeutics today announced the closing of its initial public offering of 8,625,000 shares of common stock at a public offering price of $9.00 per share, before underwriting discounts, including 1,125,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.
Inflammatory skin diseases such as psoriasis may result from abnormal activation of cell death pathways previously believed to suppress inflammation, a surprise finding that could help to develop new ways of treating these diseases.
According to the great paradigms of immunology, asthma, an allergic disease of the respiratory system, should always develop upon exposure to airborne antigens that are constantly being inhaled. However, the fact that 94 % of the Western population does not develop the disease suggests that as yet undefined mechanisms protect the respiratory tract from developing an allergic response. A team of researchers at University of Liege (Belgium), GIGA Research Center, led by Professor Fabrice Bureau, has shown that asthma is inhibited by regulatory macrophages, a cell population never previously described.
› Verified 6 days ago
Kaitlyn E Shields, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 859-268-1030 Fax: 859-269-4120 | |
Brad S. Adams, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Mr. Michael A Shilot, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
James B Lunsford, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Sarah Ratliff, Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 | |
Kevin J Stanley, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 859-268-1030 Fax: 859-269-4120 | |
Silas Shane Mcfall, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 100 Medical Center Dr, Hazard, KY 41701 Phone: 606-439-6600 |